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Infections with Candida
species
Candida spp, especially Candida albi-
cans, are commensal fungi that reside
on the skin,mucosa and gastrointestinal
tract of 30 to 50% of healthy individuals
at any given time, with everyone being
colonized at a certain moment of his/
her lifetime (Brown & Netea, 2007).
Although C. albicans is not pathogenic
under normal host conditions, it can cause severe mucosal or
systemic infections when host defense is compromised.
Mucosal infections
Mucosal infections affect the skin and mucous membranes.
Common sites for these superficial infections are the mouth,
vagina, external ear, skin and nails, of which oral candidiasis is
the most common (Odds, 1988). Mucosal infections are usually
sporadic, but some patients experience severe and recurrent
infections of the skin and oropharyngeal cavities termed chronic
mucocutaneous candidiasis (CMC). In addition, most women
suffer at least once in their lifetime from vulvovaginal candidiasis,
while up to 8% of them have recurrent infections (Sobel, 2007).
Systemic infections
In contrast to mucosal candidiasis which is highly prevalent but
does not cause high mortality, systemic infections are life
threatening, with mortality rates reaching up to 26–60% (Das
et al, 2011). When the organisms enter the blood stream they
can invade deep tissues and organs such as brain, heart and
kidneys. Considering the number of patients diagnosed each
year, Candida has emerged in the recent decades as one of
the most important pathogens in sepsis, causing significant
morbidity and mortality. Moreover, mortality due to these
severe infections has not been significantly changed in the last
decade, despite the introduction of potent antifungals such as
azoles and echinocandins (Fortu´n et al, 2012). It is currently
believed that only a combination of standard antimycotic
treatment with adjuvant immunotherapy may significantly
improve the outcome of fungal infections, and both immuno-
logical and genetic studies are needed to accomplish the
necessary understanding of the pathogenesis of these infections.
Candida albicans host defense
The C. albicans cell wall can be divided into two distinct layers:
the inner layer consisting mainly of polysaccharides like chitin,
1,3-b-glucans and 1,6-b-glucans, and the outer layer consisting
mainly of proteins that are heavily mannosylated with mannan
side-chains. These pathogen-associated molecular patterns
(PAMPs) can be recognized by several pathogen recognition
receptors (PRRs), such as the Toll-like receptors (TLRs) and
C-type lectins (CLRs) on the surface of antigen presenting cells
(APCs). TLR2 recognizes phospholipomannans (Jouault et al,
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Candida spp. are medically important fungi causing severe mucosal and life-
threatening invasive infections, especially in immunocompromised hosts. However,
not all individuals at risk develop Candida infections, and it is believed that genetic
variation plays an important role in host susceptibility. On the one hand, severe
fungal infections are associated with monogenic primary immunodeficiencies such
as defects in STAT1, STAT3 or CARD9, recently discovered as novel clinical entities.
On the other hand, more common polymorphisms in genes of the immune system
have also been associated with fungal infections such as recurrent vulvovaginal
candidiasis and candidemia. The discovery of the genetic susceptibility to Candida
infections can lead to a better understanding of the pathogenesis of the disease, as
well as to the design of novel immunotherapeutic strategies. This review is part of
the review series on host-pathogen interactions. See more reviews from this series.
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2006). N-linked mannans are recognized by the macrophage
mannose receptor (MMR) (Netea et al, 2006), with other CLRs
which can recognize mannose residues being Dectin-2 (McGreal
et al, 2006), Mincle (Wells et al, 2008), DC-specific ICAM-
grapping non-integrin (DC-SIGN) (Cambi et al, 2003) and the
soluble receptor mannose-binding lectin (MBL) (Brouwer et al,
2008). The CLR Dectin-1 recognizes b-glucan (Brown & Gordon,
2001) (Fig 1).
When a PRR recognizes its corresponding ligand, adaptor
molecules engage with the receptor. Different types of PRRs
use different adaptor molecules, which transduce a signal by
activating a kinase cascade, in order to induce the transcription
of proinflammatory cytokines. Dectin-1 signals through Syk
(Rogers et al, 2005) and caspase recruitment domain 9 (CARD9)
(Gross et al, 2006). Dectin-1 can induce cytokine production
independently of other receptors, as well as synergize with
TLRs for an optimal stimulation of the cell. When ligands are
recognized by TLRs, signals are transduced intracellularily
through adaptor proteins like myeloid differentiation factor
(MYD)88. Subsequently, a mitogen-activated protein kinase
(MAPK) response is activated leading to the nuclear transloca-
tion of transcription factors like NF-kB and c-Jun, inducing the
transcription of cytokines and chemokines (Akira et al, 2006).
Interestingly, depending on the fungal burden and amount of
hyphae formation a second MAPK phase, consisting of MKP1
and c-Fos activation, can be initiated, further promoting
proinflammatory responses (Moyes et al, 2010).
The recognition of C. albicans by cells of the innate immune
system will lead to phagocytosis (Heinsbroek et al, 2008)
and killing of the invading pathogen. At the same time, the
production of cytokines is induced that on the one hand
activate inflammation, and on the other hand engage and direct
the adaptive immune response. Activation of the caspase-1
component of the inflammasome, mediated by the intracellular
activation of the NOD-like receptor NLRP3, is a central event
leading to the processing of pro-IL-1b and pro-IL-18 into their
respective bioactive cytokines, directing the induction of Th17
and Th1 responses, respectively (Cheng et al, 2011; Lalor et al,
2011). IFN-g production by Th1 cells, and IL-17 production by
Th17 cells are important characteristics of the Candida-induced
immune response (Netea et al, 2008). Inflammasome and
Th17 activation is considered to be a central event for the
discrimination of colonization versus invasion with C. albicans
at the level of the mucosa (Gow et al, 2011).
General risk factors for Candida infections
C. albicans is an opportunistic fungal pathogen. In healthy
individuals, the immune response will usually clear infections,
but an immunocompromised immune system causes a sig-
nificant increase in the risk for Candida infections. Das et al
demonstrated that 92% of Candida bloodstream infections are
preceded by a course of broad-spectrum antibiotics (Das et al,
2011), which suppress the growth of the normal bacterial flora
and eliminates natural antagonism of fungal colonization of the
mucosa. There are several other examples in which Candida
acts as an opportunistic pathogen. For example, almost all AIDS
and oncologic patients with neutropenia suffer from orophar-
yngeal candidiasis (Grabar et al, 2008; Viscoli et al, 1999).
Furthermore, 41% of patients undergoing hematopoietic stem
cell transplantation, for which the immune system is destroyed
beforehand, suffer from one or more bloodstream infections
within the first ten years after transplantation, 4% of which are
caused by Candida spp. The crudemortality rate associatedwith





Mode of inheritance in which the presence of only one copy of a gene on
one of the 22 autosomal–non-sex chromosomes, will result in the
phenotypic expression of that gene.
Candidemia
The presence of Candida species in the blood.
Candidiasis
Fungal infection with any of the Candida species. Includes candidemia (in
case of systemic infection).
Chronic mucocutaneous candidiasis (CMC)
An immune disorder characterized by chronic infections with Candida that
are limited to mucosal surfaces, skin and nails.
Genetic variation
Variations of genomes between members of species or between groups of
species. Includes SNP (in case it is a common genetic variant), mutation
(in case it is a rare genetic variant) and copy-number variation.
Immunocompromised
State in which the immune system is not functioning properly, increasing
susceptibility to infection.
Immunodeficiency
A state in which the immune system’s ability to fight infectious disease is
compromised or entirely absent.
Immune paralysis
A state in which induction of tolerance is due to injection of large amounts
of antigen that remains poorly metabolized.
Neutropenia
An immune disorder characterized by an abnormally low level of
neutrophils.
Pathogenesis
The mechanism by which the disease is caused.
Pathogen recognition receptors (PRRs)
Proteins expressed by cells of the innate immune system, which recognize
pathogen-associated molecular patterns (PAMPs) from microbial pathogens.
Polymorphism
Having multiple alleles of a gene within a population, usually linked to
different phenotypes.
Single nucleotide polymorphism (SNP)
DNA sequence variation occurring when a single nucleotide in the genome
differs between members of a biological species or paired chromosomes in
an individual.
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Figure 1. Schematic overview of the anti-Candida albicans immune response. When Candida is recognized by Toll-like receptors (TLRs) and C-type lectin
receptors, the production of cytokines is initiated through activation of transcription factors like NF-kB. IL-1b and IL-18 first need to be cleaved by the NLRP3
inflammasome before they can be secreted. IL-2 is involved in the differentiation of all effector T-cells. The IL-2 receptor is highly expressed on regulatory T-cells
(Treg). IL-12 and IL-18 promote the differentiation of T helper 1 (Th1) cells, with IFN-g being their main product. IL-4 and IL-10 promote the differentiation of Th2
cells, while IL-10 can also suppress Th1 cells. IL-1b, IL-6 and IL-23 drive the development of Th17 cells. DOCK8 is involved in the maintenance of Th17 cells. IL-17
promotes the recruitment of neutrophils, which have tissue protective effects by the production of beta-defensins. Cytokines are recognized by cytokine receptors,
which use several adaptor molecules like STAT1, STAT3 and TYK2. PTPN22 is involved in B- and T-cell receptor signaling. Components with mutations and/or
genetic variation known to be associated with Candida infection are shown in color. APC: antigen presenting cell, BCR: B-cell receptor, CARD9: caspase recruitment
domain 9, DC-SIGN: dendritic cell-specific ICAM-grapping non-integrin, MBL: mannose binding lectin, MMR: macrophage mannose receptor, NLRP3: NACHT, LRR
and PYD domains-containing protein 3, TCR: T-cell receptor, TLR: Toll-like receptor.
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patients with systemic lupus erythematosus (SLE), which are
treated with glucocorticoids and other immunosuppressive
agents, have an increased risk for invasive fungal infections
(IFI), which are predominantly caused by Candida spp. (Fan
et al, 2012).
Not only a weakened immune system increases the risk for
Candida infections, also the extent to which individuals are
colonized with pathogens plays a significant role in the
development of candidiasis. Candidiasis typically affects
patients with prolonged hospitalization. Fifty-one percent of
Candida blood-stream infections is associated with being
admitted to the ICU (Das et al, 2011). The mean time of onset
of systemic Candida infections is 22 days after hospitalization
(Wisplinghoff et al, 2004). Furthermore, when barriers to the
outside world are damaged or breached by medical devices
or surgery, this creates a portal of entry for pathogens like
C. albicans. For instance, major abdominal surgery poses an
increased risk for systemic Candida infections, which is
underlined by the observation that in a cohort of 107 patients
with candidemia, 50% underwent recent surgery (Das et al,
2011). Another factor contributing to systemic candidiasis is the
fact that Candida spp. can form biofilms on many medical
devices like central venous catheters (CVC), contact lenses,
intrauterine devices (IUDs) (Donlan & Costerton, 2002) and
pacemakers (Glo¨ckner, 2011). Candida can even cause
prosthetic joint infections, although they are considered to
be rare (Springer & Chatterjee, 2012). Indeed, neonates on the
intensive care unit (ICU) with a central line often suffer from
infections, with the third most causative pathogen being
Candida spp. Fortunately this incidence is decreasing due to
the use of anti-fungal prophylaxis (Chitnis et al, 2012).
Genetic risk factors for Candida infections
In spite of the important role played by these risk factors, they do
not explain all Candida infections, and only a minority of
individuals at risk will eventually develop a fungal infection. It
is therefore believed that also genetic factors must play an
important role in determining the susceptibility to Candida
infections. Indeed, mutations in single genes were found to be
responsible for severe Candida infections in several primary
immunodeficiencies that display the clinical picture of mono-
genetic disorders. However, these disorders are rare, and in the
majority of patients no sole causative genetic factor can be
found. In most patients a combination of gene polymorphisms
and/or environmental factors will determine whether a patient
will develop a Candida infection. The genetic susceptibility to
more common Candida infections such as RVVC or candidemia
is likely polygenic, but the understanding of the genetic factors
that determine it is nevertheless crucial for future immuno-
therapeutic approaches in these patients.
Monogenetic disorders
Several monogenetic disorders have been described in the
literature to be associated with an increased susceptibility to
fungal infections. Glocker et al described that a homozygous
mutation in the CARD9 gene, coding for a protein downstream of
Dectin-1, results in an increased susceptibility to both mucosal
and invasive Candida infections (Glocker et al, 2009; Lanternier
et al, 2012). Disease severity in these patients is likely explained
by the fact that CARD9 is also involved in the downstream
signaling of several other CLR receptors, such as Dectin-2 and
Mincle (Robinson et al, 2009; Saijo et al, 2010; Strasser et al,
2012; Yamasaki et al, 2008), implying that CARD9 is a central
mediator of anti-Candida host defense.
Another monogenetic disorder that results in an important
primary immunodeficiency associated with Candida infections
is CMC. Both autosomal recessive and autosomal dominant
variants of the disease have been described. Mutations in the
CC-domain of STAT1, a signaling molecule downstream of the
type I and type II IFN receptor (Darnell et al, 1994), but also IL-
23 and IL-12 receptors (as heterodimer with STAT3 or STAT4),
have recently been demonstrated to be the main cause of
autosomal-dominant CMC (van de Veerdonk et al, 2011), and
these findings were confirmed by several other research groups
(Depner et al, 2012; Hirata et al, 2012; Liu et al, 2011; Martinez-
Martinez et al, 2012; Moreira et al, 2012; Okada et al, 2012;
Smeekens et al, 2011). In addition to STAT1mutations, Puel et al
demonstrated the presence of mutations in IL-17RA and IL-17F
in some unexplained CMC cases (Puel et al, 2012). In contrast,
patients with autosomal recessive autoimmune polyendocrino-
pathy candidiasis ectodermal dystrophy (APECED) not only
suffer from CMC, but also experience autoimmune phenomena
(Lilic, 2002). APECED has been linked to mutations in the
autoimmune regulator (AIRE) gene (Bjo¨rses et al, 1998) that
result in a loss-of-function phenotype, causing the production of
neutralizing autoantibodies against important cytokines with
antifungal properties such as IL-17E, IL-17F and IL-22 (Puel et al,
2010).
Another monogenetic defect resulting in a primary immu-
nodeficiency syndrome associated with Candida infections of
the skin is hyper-IgE syndrome (HIES). HIES was first described
as Job’s syndrome and is characterized by high serum IgE levels,
eczema, recurrent mucosal infections with C. albicans, and skin
and pulmonary infections with Staphylococcus aureus (Davis
et al, 1966). There are a number of mutations known to be
associated with HIES. Several mutations have been found in
STAT3 (Holland et al, 2007; Minegishi et al, 2007), a signaling
molecule downstream of the IL-23 receptor, resulting in absent
IL-17 production (de Beaucoudrey et al, 2008; Ma et al, 2008;
Milner et al, 2008; Sharfe et al, 1997). Other genes which have
been associated with HIES include dedicator of cytokinesis
(DOCK)8 that codes for a protein involved in Th17 polarization
(Engelhardt et al, 2009) and TYK2 (Minegishi et al, 2006),
coding for a Janus kinase (JAK) downstream of the IL-12
receptor (Shimoda et al, 2000). All in all, defective Th17
responses underlie both CMC and HIES, two immunodeficien-
cies associated with severe, chronic, mucosal Candida infec-
tions. This emphasizes the importance of the Th17 response in
mucosal Candida immunity.
Also mutations in genes coding for cytokines and their
receptors have been described to be associated with Candida
infections. For example, IL-12Rb1 deficiency has been linked to
Review www.embomolmed.org
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mucocutaneous Candida infections, and these patients also
have increased susceptibility for invasive candidiasis (Rodrı´-
guez-Gallego et al, 2012). Sharfe et al described a patient with a
deletion in the CD25 gene, suffering from esophageal candi-
diasis. CD25 is the a-subunit of the IL-2 receptor, which is
constitutively expressed on T regulatory cells (Sakaguchi et al,
1995). Furthermore, IL-2 is involved in the differentiation of
effector T cells. Although Sharfe et al only described a single
patient, this again emphasizes the importance of T cells in the
anti-Candida host response. A complete overview of mono-
genetic disorders causing fungal infections is depicted in Table 1
and Fig 1.
Common genetic variants and susceptibility to Candida
infections
Despite the presence of primary immunodeficiency syndromes
with fungal infections, the vast majority of fungal infections is
not present in these individuals, but are common diseases with a
polygenic pattern of increased susceptibility. Several studies
have been published showing a link between genetic variation
and an increased risk for Candida infections, with different
genetic pattern being discerned between mucosal and systemic
candidiasis. An example of this dichotomy is the role of a
Dectin-1 polymorphism for susceptibility to mucosal, but not
systemic, candidiasis. We have recently described a family in
which its members suffered from recurrent vulvo-vaginal
candidiasis (RVVC) and onychomycosis. Their symptoms could
be explained by an early stop codon in Dectin-1 (Y238X) that
resulted in defective b-glucan recognition and Th17 responses.
Interestingly, this polymorphism is present in up to 8% of
the Europeans and up to 40% of some sub-Saharan African
populations (Ferwerda et al, 2009), being associated with
mucosal Candida colonization and treatment in haematopoetic
patients (Plantinga et al, 2009), but not with systemic
candidiasis (Rosentul et al, 2011).
Genetic variation localized in other PRRs, such as the TLRs,
has also been associated with an increased susceptibility to
fungal infections. Three single nucleotide polymorphisms
(SNPs) in the TLR1 gene have been shown to influence
susceptibility to candidemia, presumably mediated by
decreased levels of IL-8 and IFN-g (Plantinga et al, 2012).
However, these findings need to be replicated in independent
studies, and it is unclear which component of Candida is
recognized by TLR1. A similar observation has been made for
TLR2 and TLR4, which recognize phospholipomannans and
O-linked mannans, respectively. The R753Q TLR2 polymorph-
ism increased the risk for candidemia in one small study through
decreased IFN-g and IL-8 levels (Woehrle et al, 2008), and two
SNPs in the TLR4 gene were shown to be a risk factor for
candidemia through increased IL-10 production (Van der Graaf
et al, 2006), but these observations were not replicated in a
larger study of patients (Plantinga et al, 2012). Nahum et al
suggested that the L412F TLR3 polymorphism increases the risk
for CMC, an effect mediated by decreased IFN-g production
(Nahum et al, 2011). Furthermore, variable number of tandem
repeats in MBL2 gene that codes for the soluble PRR MBL has
been linked to RVVC in two separate studies (Babula et al, 2003;
Giraldo et al, 2007). Finally, length polymorphisms in theNLPR3
gene, coding for the receptor subunit of the NLRP3 inflamma-
some, can increase the risk for RVVC (Lev-Sagie et al, 2009).
In addition to the first step of pathogen recognition, genetic
variation in several cytokines has been linked to an increased
risk for Candida infections. Choi et al demonstrated that the
1089T/G, 589C/T and the 33C/T polymorphisms in IL-4
are associated with chronic disseminated candidiasis (Choi
et al, 2003). Interestingly, the 589T/C SNP has also been
www.embomolmed.org Review
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Table 1. Monogenetic disorders
Gene Mutation Mode of inheritance Phenotype Disease Refs.
AIRE R257X Autosomal-dominant Autoantibodies against IL-17
and IL-22
CMC Nagamine et al (1997),












Glocker et al (2009)
Lanternier et al (2012)
CD25 Deletion (60–64) Autosomal recessive Reduced number of CD4þ cells Candida esophagitis Sharfe et al (1997)
DOCK8 Multiple deletions and
point mutations
Autosomal-recessive Reduced Th17 cells Hyper IgE syndrome Engelhardt et al (2009)
IL-12Rb1 Multiple point
mutations
Autosomal-recessive Low levels of IFN-g Mucosal candidiasis Rodrı´guez-Gallego et al (2012)
IL-17RA Q284X Autosomal-recessive Absent IL-6 and GRO-a
production
CMC Puel et al (2011)
IL-17F S65L Autosomal-dominant Reduced IL-6 and GRO-a
production
CMC Puel et al (2011)
STAT1 R274W A267V Autosomal-dominant Reduced IL-17, IL-22 and
IFN-g production
CMC van de Veerdonk et al (2011)
STAT3 Multiple point
mutations
Autosomal-dominant Reduced IL-17 production HIES Holland et al (2007)
TYK2 Deletion (550–553) Autosomal-recessive Reduced Th1 and Type I
IFN responses
HIES Minegishi et al (2006)
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demonstrated to pose a risk for RVVC (Babula et al, 2005). The
1082A/G polymorphism in the anti-inflammatory cytokine
gene IL-10 and the 274INS/DEL polymorphism in IL-12b,
are associated with persisting candidemia (Johnson et al, 2012).
These data strongly suggest that the balance between pro- and
anti-inflammatory cytokines represent an important component
of host defense against both mucosal and systemic candidiasis.
The 44C/G polymorphism in DEFB1, coding for beta-
defensin 1, is correlated with increased Candida carriage
(Jurevic et al, 2003). The exact underlying mechanism is
unclear, but in general beta-defensins are secreted by neu-
trophils and epithelial cells and contribute to epithelial
immunity. The R620W polymorphism in PTPN22, a protein
involved in T-cell and B-cell receptor signaling, was suggested to
be associated with an increased risk for CMC. Although the
potential mechanism of this association is unclear (Nahum et al,
2008). A complete overview of common genetic variants
associated with fungal infection is depicted in Table 2 and Fig 1.
Future developments
The current body of evidence has provided many new insights
into the working mechanism of the anti-Candida immune
response. These new insights can pinpoint novel potential
targets for immunotherapy. For example, several studies have
demonstrated a correlation between decreased IFN-g levels and
an increased risk for systemic Candidiasis (Johnson et al, 2012;
Woehrle et al, 2008). A double-blind, randomized, placebo-
controlled study is currently being performed using adjuvant
IFN-g therapy in sepsis. It would be also very relevant to
try and reverse the immunoparalysis (Leentjens et al, 2012).
This suggests that IFN-g is a promising treatment option in
sepsis-induced immune paralysis. We are currently investigat-
ing the efficacy of recombinant IFN-g in patients with Candida
sepsis.
Despite the significant progress of the last few years for
uncovering susceptibility to fungal infections, there are still a
significant number of Candida infections for which the
environmental and/or genetic risk factors are not yet deci-
phered. Even more importantly, in spite of current treatment
regimens, mortality rates associated with systemic infections are
still very high, and in order to improve diagnostic- and treatment
options, future efforts should be directed towards gaining more
insight into the anti-Candida host immune response. This can
be achieved in several ways. Discovering novel mutations
that underlie monogenetic disorders associated with Candida
infections can generate crucial information about a particular
gene or protein, and the pathway in which this protein is
involved. For example, the use of next generation sequencing
and whole exome sequencing to discover STAT1mutations as a
cause of CMC (van de Veerdonk et al, 2011), has also led in the
understanding of its role for the generation of Th1 and Th17
responses and the anti-Candida host defense (Smeekens et al,
2011). This discovery can lead to novel approaches to the
therapy of CMC, some of them being currently tested.
Of course, the list of existing monogenetic disorders is
relatively small, as the majority of Candida cases are likely
polygenic and/or multifactorial. In order to investigate this type
of disorders other methods will have to be employed such as
genome-wide association studies (GWAS), deep sequencing,
and systems biology. We have recently used a combination of
transcriptional analysis and functional genomics to demonstrate
that type I IFNs play an important role in the anti-Candida host
defense (Smeekens et al, 2013). Stimulation of circulating
leukocytes with C. albicans led to a transcription profile with
Review www.embomolmed.org
Genetic susceptibility
Table 2. Common genetic variants
Gene SNP (rs-number) Phenotype Disease Refs.
Dectin-1 Y238X (rs16910526) Decreased IL-1b and Th17 responses Candida colonization Plantinga et al (2009)











Babula et al (2005)
Choi et al (2003)
IL-10 1082A/G (rs1800896) Higher Candida-induced IL-10 production Persisting candidemia Johnson et al (2012)
IL-12B 2724INS/DEL (rs17860508) Lower Candida-induced IFN-g production Persisting candidemia Johnson et al (2012)
MBL2 Variable number of tandem
repeats in intron 4
Reduced vaginal MBL levels RVVC Babula et al (2003),
Giraldo et al (2007)
NLPR3 Length polymorphism Impaired IL-1b production RVVC Lev-Sagie et al (2009)




Decreased production of IL-1b, IL-6 and
IL-8 after TLR1-TLR2 stimulation
Increased susceptibility
to candidemia
Plantinga et al (2012)
TLR2 R753Q (rs5743708) Decreased levels of IFN-g and IL-8 Increased susceptibility
to candidemia
Woehrle et al (2008)
TLR3 L412F (rs3775291) Decreased IFN-g levels Increased risk for CMC Nahum et al (2011, 2012)
TLR4 D299G (rs4986790),
Y399I (rs4986791)
Increased IL-10 production Increased susceptibility
to candidemia
Van der Graaf et al (2006)
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overrepresentation of genes from the type I IFN pathway.
Subsequently, we showed that polymorphisms in these genes
modify Candida-induced cytokine production and influence
susceptibility to systemic Candida infections. Furthermore,
validation studies showed that type I IFNs skew Candida-
induced cytokine responses from Th17 toward Th1, while
STAT1-deficient CMC patients display defective expression
of genes in the type I IFN pathway. This ‘systems approach’,
that integrates the information on anti-Candida host defense
from several types of studies, provides information with
respect to potential novel anti-Candida immune responses
that may represent targets for immunotherapy. It is to be
expected that an integration of efforts from immunology,
genetics, microbiology and systems biology will represent the
novel level of understanding of host defense against fungal
(and other) pathogens, improving the outcome of these severe
infections.
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